

## APC/Cyanine7 anti-human TIGIT (VSTM3)

**Catalog # /** 2463670 / 100 tests  
**Size:** 2463665 / 25 tests

**Clone:** A15153G

**Isotype:** Mouse IgG2a, κ


**Immunogen:** Recombinant Human TIGIT.

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with APC/Cyanine7 under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD3 PE and TIGIT (VSTM3) (clone A15153G) APC/Cyanine7 (left) or mouse IgG2a, κ APC/Cyanine7 isotype control (right).

## Applications:

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** This clone can suppress anti-CD3 induced T cell proliferation in vitro based on in-house testing.

This clone has been tested in-house and determined to not be suitable for applications in immunohistochemistry of paraffin-embedded ti

**Application References:** 1. Stamm H, et al. 2018. *Oncogene*. [Pubmed](#)

**Description:** T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSTM3 or WUCAM, is a 26 kD, type I transmembrane protein and is a member of the PVR (poliovirus receptor) family of immunoglobulin-like domain containing proteins. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. TIGIT is a negative regulator of NK and T cell activation. Expression of TIGIT is associated with decreased functionality of CD8 T cells in chronic viral infection and tumors. TIGIT also promotes the differentiation of tolerogenic phenotype in dendritic cells with an increased secretion of IL-10 and a diminished production of IL-12.

**Antigen References:** 1. Stanitsky N, et al. 2009. *Proc. Natl. Acad. Sci.* 106:17858.  
 2. Yu X, et al. 2009. *Nat. Immunol.* 10:48.  
 3. Johnston R, et al. 2014. *Cancer Cell.* 26:923.